DOCSLIB.ORG

Supplement Al Table S3. Includes Gene and Rank Lists from GSEA Analyses Found in Figure 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplement Al Table S3. Includes Gene and Rank Lists from GSEA Analyses Found in Figure 3 Supplement al Table S3. Includes Gene and rank lists from GSEA analyses found in Figure 3. All comparison s were made relative to Mock and each list contained all significant differentiall y expressed genes as revealed by DESeq2 NAME SYMBOL TITLE RANK IN GENERANK LIST METRICRUNNING SCORE ES CORE ENRICHMENT row_0 CD47 CD47 molecule [Source:HGNC10 3567.07446 Symbol;Acc:HGNC:1682]0.2492651 Yes row_1 GBP4 guanylate binding protein150 4 [Source:HGNC339.55188 Symbol;Acc:HGNC:20480]0.26279798 Yes row_2 LAMP3 lysosomal associated membrane649 103.491318 protein 3 [Source:HGNC0.23327412 NoSymbol;Acc:HGNC:14582] row_3 NCOA7 nuclear receptor coactivator909 7 [Source:HGNC74.330658 Symbol;Acc:HGNC:21081]0.2193566 No row_4 EIF2AK2 eukaryotic translation initiation1216 50.5981865 factor 2 alpha kinase0.2003048 2 [Source:HGNCNo Symbol;Acc:HGNC:9437] row_5 IRF7 interferon regulatory factor1620 7 [Source:HGNC-9.9604034 Symbol;Acc:HGNC:6122]0.17124143 No row_6 NMI N-myc and STAT interactor1855 [Source:HGNC-12.753016 Symbol;Acc:HGNC:7854]0.15485439 No row_7 CMPK2 cytidine/uridine monophosphate2153 -15.278153 kinase 2 [Source:HGNC0.1339918 Symbol;Acc:HGNC:27015]No row_8 SP110 SP110 nuclear body protein2228 [Source:HGNC-15.843646 Symbol;Acc:HGNC:5401]0.12963733 No row_9 PSMB8 proteasome 20S subunit2344 beta -16.8564728 [Source:HGNC0.12232602 Symbol;Acc:HGNC:9545]No row_10 TXNIP thioredoxin interacting 2376protein -17.118099[Source:HGNC0.12123642 Symbol;Acc:HGNC:16952]No row_11 IFI35 interferon induced protein2772 35 [Source:HGNC-20.530298 0.09350465 Symbol;Acc:HGNC:5399]No row_12 MOV10 Mov10 RISC complex 2838RNA helicase-21.055349 [Source:HGNC0.09018011 Symbol;Acc:HGNC:7200]No row_13 PARP9 poly(ADP-ribose) polymerase3230 family-24.617743 member 0.063030219 [Source:HGNCNo Symbol;Acc:HGNC:24118] row_14 DHX58 DExH-box helicase 58 3256[Source:HGNC-24.914341 Symbol;Acc:HGNC:29517]0.06293012 No row_15 PARP12 poly(ADP-ribose) polymerase3329 family-25.645409 member 0.0594103312 [Source:HGNCNo Symbol;Acc:HGNC:21919] row_16 TRAFD1 TRAF-type zinc finger domain3357 -25.921444containing 1 [Source:HGNC0.05923313 No Symbol;Acc:HGNC:24808] row_17 IFIH1 interferon induced with3386 helicase-26.098246 C domain 1 0.05899447[Source:HGNCNo Symbol;Acc:HGNC:18873] row_18 IFIT2 interferon induced protein3731 with-29.999317 tetratricopeptide0.03569269 repeats 2 [Source:HGNCNo Symbol;Acc:HGNC:5409] row_19 USP18 ubiquitin specific peptidase4191 18-35.513855 [Source:HGNC0.00428468 Symbol;Acc:HGNC:12616]No row_20 TMEM140 transmembrane protein4465 140 [Source:HGNC-38.731377 Symbol;Acc:HGNC:21870]-0.0131618 No row_21 IRF2 interferon regulatory factor4507 2 [Source:HGNC-39.162704 Symbol;Acc:HGNC:6117]-0.0134448 No row_22 IFI30 IFI30 lysosomal thiol reductase4530 -39.44434[Source:HGNC-0.012305 Symbol;Acc:HGNC:5398]No row_23 RSAD2 radical S-adenosyl methionine4669 -40.988914domain containing-0.0196235 2 [Source:HGNCNo Symbol;Acc:HGNC:30908] row_24 GMPR guanosine monophosphate4963 reductase-44.384579 [Source:HGNC-0.0381508 Symbol;Acc:HGNC:4376]No row_25 TRIM21 tripartite motif containing5174 21 [Source:HGNC-47.212055 Symbol;Acc:HGNC:11312]-0.0503503 No row_26 C1S complement C1s [Source:HGNC5316 -49.296707 Symbol;Acc:HGNC:1247]-0.0573081 No row_27 TDRD7 tudor domain containing5393 7 [Source:HGNC-50.331558 Symbol;Acc:HGNC:30831]-0.0593931 No row_28 DDX60 DExD/H-box helicase 605466 [Source:HGNC-51.355556 Symbol;Acc:HGNC:25942]-0.061111 No row_29 IFI44 interferon induced protein5702 44 [Source:HGNC-55.15657 -0.0745999Symbol;Acc:HGNC:16938]No row_30 ELF1 E74 like ETS transcription6123 factor-63.081059 1 [Source:HGNC-0.1011957 Symbol;Acc:HGNC:3316]No row_31 TENT5A terminal nucleotidyltransferase6177 -63.9525685A [Source:HGNC-0.1006275 Symbol;Acc:HGNC:18345]No row_32 ISG15 ISG15 ubiquitin like modifier6479 [Source:HGNC-70.364784 Symbol;Acc:HGNC:4053]-0.1179247 No row_33 NUB1 negative regulator of ubiquitin6643 -73.920769like proteins 1 -0.1247814[Source:HGNCNo Symbol;Acc:HGNC:17623] row_34 PLSCR1 phospholipid scramblase6686 1 [Source:HGNC-74.892319 Symbol;Acc:HGNC:9092]-0.1226341 No row_35 UBA7 ubiquitin like modifier activating6764 -76.634247 enzyme 7 [Source:HGNC-0.1229496 Symbol;Acc:HGNC:12471]No row_36 BST2 bone marrow stromal cell7257 antigen-89.166603 2 [Source:HGNC-0.1530343 Symbol;Acc:HGNC:1119]No row_37 TRIM26 tripartite motif containing7484 26 [Source:HGNC-94.926094 Symbol;Acc:HGNC:12962]-0.1630713 No row_38 IFI44L interferon induced protein8103 44 like-114.26035 [Source:HGNC-0.2007024 Symbol;Acc:HGNC:17817]No row_39 TAP1 transporter 1, ATP binding8158 cassette-116.07171 subfamily-0.1965552 B member [Source:HGNCNo Symbol;Acc:HGNC:43] row_40 UBE2L6 ubiquitin conjugating enzyme8442 -126.97215E2 L6 [Source:HGNC-0.2085557 Symbol;Acc:HGNC:12490]No row_41 MVB12A multivesicular body subunit8540 12A-130.94151 [Source:HGNC-0.2065419 Symbol;Acc:HGNC:25153]No row_42 LY6E lymphocyte antigen 6 family8551 member-131.21906 E [Source:HGNC-0.1980837 Symbol;Acc:HGNC:6727]No row_43 SLC25A28 solute carrier family 25 8838member-142.59526 28 [Source:HGNC-0.2092107 Symbol;Acc:HGNC:23472]No row_44 HLA-C major histocompatibility8881 complex,-144.32292 class I, C [Source:HGNC-0.2021973 No Symbol;Acc:HGNC:4933] row_45 ADAR adenosine deaminase RNA9061 specific-152.67032 [Source:HGNC-0.2047163 Symbol;Acc:HGNC:225]No row_46 IRF9 interferon regulatory factor9127 9 [Source:HGNC-155.57648 Symbol;Acc:HGNC:6131]-0.1986128 No row_47 HELZ2 helicase with zinc finger9257 2 [Source:HGNC-161.26155 Symbol;Acc:HGNC:30021]-0.1968371 No row_48 CSF1 colony stimulating factor9351 1 [Source:HGNC-166.25504 Symbol;Acc:HGNC:2432]-0.192053 No row_49 IFITM1 interferon induced transmembrane9615 -181.3557 protein 1 [Source:HGNC-0.1987649 No Symbol;Acc:HGNC:5412] row_50 TRIM25 tripartite motif containing9719 25 [Source:HGNC-186.39101 Symbol;Acc:HGNC:12932]-0.1933079 No row_51 PSME1 proteasome activator 10066subunit 1-210.09407 [Source:HGNC-0.2041352 Symbol;Acc:HGNC:9568]No row_52 LAP3 leucine aminopeptidase10302 3 [Source:HGNC-228.00081 Symbol;Acc:HGNC:18449]-0.2055101 No row_53 PSME2 proteasome activator 10379subunit 2-233.03122 [Source:HGNC-0.1947904 Symbol;Acc:HGNC:9569]No row_54 IFITM2 interferon induced transmembrane10833 -273.94855 protein 2 [Source:HGNC-0.2090443 No Symbol;Acc:HGNC:5413] row_55 PSMA3 proteasome 20S subunit10903 alpha-281.48401 3 [Source:HGNC-0.1944117 Symbol;Acc:HGNC:9532]No row_56 RNF31 ring finger protein 31 10937[Source:HGNC-285.12659 Symbol;Acc:HGNC:16031]-0.1768652 No row_57 WARS1 tryptophanyl-tRNA synthetase11210 -315.723791 [Source:HGNC-0.1748244 Symbol;Acc:HGNC:12729]No row_58 CMTR1 cap methyltransferase11626 1 [Source:HGNC-367.3056 Symbol;Acc:HGNC:21077]-0.1797289 No row_59 CD74 CD74 molecule [Source:HGNC11806 Symbol;Acc:HGNC:1697]-395.2486 -0.1652464 No row_60 STAT2 signal transducer and11860 activator-407.09146 of transcription-0.1406289 2 [Source:HGNCNo Symbol;Acc:HGNC:11363] row_61 OGFR opioid growth factor receptor11971 [Source:HGNC-428.81546 -0.1186982Symbol;Acc:HGNC:15768]No row_62 CNP 2',3'-cyclic nucleotide12632 3' phosphodiesterase-632.13733 -0.1231348[Source:HGNCNo Symbol;Acc:HGNC:2158] row_63 IFITM3 interferon induced transmembrane12925 -789.66852 protein 3 [Source:HGNC-0.0893539 No Symbol;Acc:HGNC:5414] row_64 B2M beta-2-microglobulin 13022[Source:HGNC-870.55383 Symbol;Acc:HGNC:914]-0.0354294 No row_65 LGALS3BP galectin 3 binding protein13226 [Source:HGNC-1119.8126 Symbol;Acc:HGNC:6564]0.02806276 No CORE ENRICHMENT NAME SYMBOL TITLE RANK IN GENERANK LIST METRICRUNNING SCORE ES CORE ENRICHMENT row_0 IRF1 interferon regulatory factor144 1 [Source:HGNC2.95010591 Symbol;Acc:HGNC:6116]-0.0030284 No row_1 GBP4 guanylate binding protein352 4 [Source:HGNC1.87184191 Symbol;Acc:HGNC:20480]-0.0144334 No row_2 CASP8 caspase 8 [Source:HGNC666 Symbol;Acc:HGNC:1509]1.21339834 -0.036492 No row_3 CMPK2 cytidine/uridine monophosphate832 0.99999046 kinase 2 [Source:HGNC-0.0470476 Symbol;Acc:HGNC:27015]No row_4 GMPR guanosine monophosphate1177 reductase-2.0803921 [Source:HGNC-0.0690678 Symbol;Acc:HGNC:4376]No row_5 IFI35 interferon induced protein1304 35 [Source:HGNC-2.2203798 -0.0727921Symbol;Acc:HGNC:5399]No row_6 PARP12 poly(ADP-ribose) polymerase1433 family-2.3384011 member -0.076329212 [Source:HGNCNo Symbol;Acc:HGNC:21919] row_7 IRF7 interferon regulatory factor1547 7 [Source:HGNC-2.4566913 Symbol;Acc:HGNC:6122]-0.0782839 No row_8 PROCR protein C receptor [Source:HGNC1838 -2.6856821 Symbol;Acc:HGNC:9452]-0.0940736 No row_9 RIPK2 receptor interacting serine/threonine2026 -2.8110082 kinase 2 -0.1010426[Source:HGNCNo Symbol;Acc:HGNC:10020] row_10 IL4R interleukin 4 receptor [Source:HGNC2494 -3.1426797 Symbol;Acc:HGNC:6015]-0.1299884 No row_11 TRIM25 tripartite motif containing2551 25 [Source:HGNC-3.2033882 Symbol;Acc:HGNC:12932]-0.1250456 No row_12 BST2 bone marrow stromal cell3214 antigen-3.5974441 2 [Source:HGNC-0.1686305 Symbol;Acc:HGNC:1119]No row_13 TRIM5 tripartite motif containing3453 5 [Source:HGNC-3.7460012 Symbol;Acc:HGNC:16276]-0.1769991 No row_14 IRF9 interferon regulatory factor4028 9 [Source:HGNC-4.0084872 Symbol;Acc:HGNC:6131]-0.2121432 No row_15 PLSCR1 phospholipid scramblase4221 1 [Source:HGNC-4.0928836 Symbol;Acc:HGNC:9092]-0.2157066 No row_16 UBA7 ubiquitin like modifier activating4272 -4.1143513 enzyme 7 [Source:HGNC-0.20756 Symbol;Acc:HGNC:12471]No row_17 CMTR1 cap methyltransferase 14466 [Source:HGNC-4.1947112 Symbol;Acc:HGNC:21077]-0.2109023 No row_18 B2M beta-2-microglobulin [Source:HGNC4509 -4.2108688 Symbol;Acc:HGNC:914]-0.2018123 No row_19 C1S complement C1s [Source:HGNC5061
Load more

Recommended publications
  • Upregulation of Cyclin T1/CDK9 Complexes During T Cell Activation
    Oncogene (1998) 17, 3093 ± 3102 ã 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 http://www.stockton-press.co.uk/onc Upregulation of cyclin T1/CDK9 complexes during T cell activation Judit Garriga1,2, Junmin Peng4, Matilde ParrenÄ o1,2, David H Price4, Earl E Henderson1,3 and Xavier GranÄ a*,1,2 1Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, USA; 2Department of Biochemistry, Temple University School of Medicine, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, USA; 3Microbiology and Immunology, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, Pennsylvania 19140, USA and 4Department of Biochemistry, University of Iowa, Iowa City, Iowa 52242, USA Cyclin T1 has been identi®ed recently as a regulatory date in response to intracellular or extracellular signals subunit of CDK9 and as a component of the transcrip- in mammalian cells, although it has been shown that tion elongation factor P-TEFb. Cyclin T1/CDK9 com- the levels of cyclin C mRNA are stimulated by serum plexes phosphorylate the carboxy terminal domain and cytokines (Lew et al., 1991; Liu et al., 1998). All (CTD) of RNA polymerase II (RNAP II) in vitro. Here cyclin/CDK pairs involved in transcription are able to we report that the levels of cyclin T1 are dramatically phosphorylate the C-terminal domain (CTD) of RNA upregulated by two independent signaling pathways polymerase II (RNAP II) in vitro. Multiple kinases triggered respectively by PMA and PHA in primary seem to phosphorylate the CTD of RNAP II in vivo in human peripheral blood lymphocytes (PBLs).
    [Show full text]
  • S41467-020-18249-3.Pdf
    ARTICLE https://doi.org/10.1038/s41467-020-18249-3 OPEN Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain Lei Zhao1,2,17, Zhongqi Li 1,2,17, Joaquim S. L. Vong2,3,17, Xinyi Chen1,2, Hei-Ming Lai1,2,4,5,6, Leo Y. C. Yan1,2, Junzhe Huang1,2, Samuel K. H. Sy1,2,7, Xiaoyu Tian 8, Yu Huang 8, Ho Yin Edwin Chan5,9, Hon-Cheong So6,8, ✉ ✉ Wai-Lung Ng 10, Yamei Tang11, Wei-Jye Lin12,13, Vincent C. T. Mok1,5,6,14,15 &HoKo 1,2,4,5,6,8,14,16 1234567890():,; The molecular signatures of cells in the brain have been revealed in unprecedented detail, yet the ageing-associated genome-wide expression changes that may contribute to neurovas- cular dysfunction in neurodegenerative diseases remain elusive. Here, we report zonation- dependent transcriptomic changes in aged mouse brain endothelial cells (ECs), which pro- minently implicate altered immune/cytokine signaling in ECs of all vascular segments, and functional changes impacting the blood–brain barrier (BBB) and glucose/energy metabolism especially in capillary ECs (capECs). An overrepresentation of Alzheimer disease (AD) GWAS genes is evident among the human orthologs of the differentially expressed genes of aged capECs, while comparative analysis revealed a subset of concordantly downregulated, functionally important genes in human AD brains. Treatment with exenatide, a glucagon-like peptide-1 receptor agonist, strongly reverses aged mouse brain EC transcriptomic changes and BBB leakage, with associated attenuation of microglial priming. We thus revealed tran- scriptomic alterations underlying brain EC ageing that are complex yet pharmacologically reversible.
    [Show full text]
  • Quantitative Proteomics Identify the Possible Tumor Suppressive Role of Protease-Activated Receptor-4 in Esophageal Squamous Cell Carcinoma Cells
    Pathology & Oncology Research (2019) 25:937–943 https://doi.org/10.1007/s12253-018-0395-7 ORIGINAL ARTICLE Quantitative Proteomics Identify the Possible Tumor Suppressive Role of Protease-Activated Receptor-4 in Esophageal Squamous Cell Carcinoma Cells Ming Wang1 & Shuhong An1 & Diyi Wang2 & Haizhen Ji3 & Min Geng1 & Xingjing Guo 3 & Zhaojin Wang1 Received: 28 November 2017 /Accepted: 21 February 2018 /Published online: 4 March 2018 # Arányi Lajos Foundation 2018 Abstract Exposure to carcinogens of tobacco smoke may result in methylation of protease-activated receptors-4 (PAR4) gene and further induces the loss of PAR4 expression, which is considered to be involved in carcinogenesis of esophageal squamous cell carcinoma (ESCC). Here we employed a TMT-based quantitative proteomic approach to identify PAR4-regulated changes of proteomic profiles in ESCC cells and to identify potentially therapeutic value. A total of 33 proteins were found significantly changed with 15 up-regulated and 18 down-regulated in PAR4-activating peptide (PAR4-AP) treated ESCC cells compared with controls. Bioinformatics analysis showed that key higher expressed proteins included those associated with apoptosis and tumor suppressor (e.g. CASP9), and lower expressed proteins included those associated with anti-apoptosis, autophagy and promoting cell proliferation (e.g. CHMP1B, PURA, PARG and HIST1H2AH). Western blot verified changes in five representative proteins including CASP9, CHMP1B, PURA, PARG and HIST1H2AH. Immunohistochemistry analysis showed that CHMP1B, PURA, PARG and HIST1H2AH expression in ESCC tissues were significantly higher than those in adjacent nontumorous tissues. Our findings will be helpful in further investigations into the functions and molecular mechanisms of PAR4 in ESCC.
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • HIV-1 Tat: Its Dependence on Host Factors Is Crystal Clear
    Viruses 2010, 2, 2226-2234; doi:10.3390/v2102226 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Commentary HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear Iván D’Orso and Alan D. Frankel * Department of Biochemistry and Biophysics, University of California, 600 16th Street, San Francisco, CA 94158-2280, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-415-476-9994; Fax: +1-415-514-4112. Received: 2 September 2010; in revised form: 1 October 2010 / Accepted: 1 October 2010 / Published: 6 October 2010 Abstract: HIV-1 transcription is regulated at the level of elongation by the viral Tat protein together with the cellular elongation factor P-TEFb, which is composed of cyclin T1 and Cdk9 subunits. The crystal structure of a Tat:P-TEFb complex (Tahirov, T.H.; Babayeva, N.D.; Varzavand, K.; Cooper, J.J.; Sedore, S.C.; and Price, D.H. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 2010, 465, 747-751.) reveals molecular details of Tat and its interactions that have eluded investigators for more than two decades and provides provocative insights into the mechanism of Tat activation. Keywords: HIV-1; Tat; transcription; P-TEFb; retroviruses HIV-1, like many viruses, co-opts the cellular machinery to orchestrate its life cycle, including its transcriptional program, and the recent crystal structure of a viral-host protein complex has revealed new facets of this interplay [1]. In this case, the virally encoded Tat protein recruits the host factor positive transcription elongation factor b (P-TEFb) to an RNA hairpin formed at the 5’-end of nascent viral RNAs (TAR) to activate a switch to transcription elongation [2].
    [Show full text]
  • Clinical Characterization of Chromosome 5Q21.1–21.3 Microduplication: a Case Report
    Open Medicine 2020; 15: 1123–1127 Case Report Shuang Chen, Yang Yu, Han Zhang, Leilei Li, Yuting Jiang, Ruizhi Liu, Hongguo Zhang* Clinical characterization of chromosome 5q21.1–21.3 microduplication: A case report https://doi.org/10.1515/med-2020-0199 Keywords: chromosome 5, prenatal diagnosis, microdu- received May 20, 2020; accepted September 28, 2020 plication, genetic counseling Abstract: Chromosomal microdeletions and microdupli- cations likely represent the main genetic etiologies for children with developmental delay or intellectual dis- ability. Through prenatal chromosomal microarray ana- 1 Introduction lysis, some microdeletions or microduplications can be detected before birth to avoid unnecessary abortions or Chromosomal microdeletions,microduplications,and birth defects. Although some microdeletions or microdu- unbalanced rearrangements represent the main genetic plications of chromosome 5 have been reported, nu- etiological factors for children with developmental delay [ ] - merous microduplications remain undescribed. We de- or intellectual disability 1 . Currently, chromosomal mi ( ) fi - - scribe herein a case of a 30-year-old woman carrying a croarray analysis CMA is considered a rst tier diag [ ] - fetus with a chromosome 5q21.1–q21.3 microduplication. nostic tool for these children 2 . Through prenatal diag Because noninvasive prenatal testing indicated a fetal nosis of CMA, some microdeletions or microduplications - chromosome 5 abnormality, the patient underwent am- can be detected before birth to avoid unnecessary abor [ ] niocentesis at 22 weeks 4 days of gestation. Karyotyping tions or birth defects 3 . The clinical features of some and chromosomal microarray analysis were performed on chromosome 5 microduplications have been described [ – ] [ ] amniotic fluid cells. Fetal behavioral and structural ab- previously 4 8 .
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • PUR Promotes the Transcriptional Activation of PCK2 in Esophageal
    G C A T T A C G G C A T genes Article PURα Promotes the Transcriptional Activation of PCK2 in Esophageal Squamous Cell Carcinoma Cells Yan Sun , Jiajia Gao , Zongpan Jing, Yan Zhao, Yulin Sun and Xiaohang Zhao * State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; [email protected] (Y.S.); [email protected] (J.G.); [email protected] (Z.J.); [email protected] (Y.Z.); [email protected] (Y.S.) * Correspondence: [email protected]; Tel.: +86-106-7709-015 Received: 5 September 2020; Accepted: 30 October 2020; Published: 31 October 2020 Abstract: Esophageal squamous cell carcinoma (ESCC) is one of the most lethal gastrointestinal malignancies due to its characteristics of local invasion and distant metastasis. Purine element binding protein α (PURα) is a DNA and RNA binding protein, and recent studies have showed that abnormal expression of PURα is associated with the progression of some tumors, but its oncogenic function, especially in ESCC progression, has not been determined. Based on the bioinformatic analysis of RNA-seq and ChIP-seq data, we found that PURα affected metabolic pathways, including oxidative phosphorylation and fatty acid metabolism, and we observed that it has binding peaks in the promoter of mitochondrial phosphoenolpyruvate carboxykinase (PCK2). Meanwhile, PURα significantly increased the activity of the PCK2 gene promoter by binding to the GGGAGGCGGA motif, as determined though luciferase assay and ChIP-PCR/qPCR. The results of Western blotting and qRT-PCR analysis showed that PURα overexpression enhances the protein and mRNA levels of PCK2 in KYSE510 cells, whereas PURα knockdown inhibits the protein and mRNA levels of PCK2 in KYSE170 cells.
    [Show full text]
  • PURA Gene Purine Rich Element Binding Protein A
    PURA gene purine rich element binding protein A Normal Function The PURA gene provides instructions for making a protein called Pur-alpha (Pura ), which is able to attach (bind) to DNA and RNA (a molecular cousin of DNA). This protein has multiple roles in cells, including controlling the activity of genes (gene transcription) and aiding in the copying (replication) of DNA. The Pura protein is important for normal brain development. The protein helps direct the growth and division of nerve cells (neurons). It may also be involved in the formation or maturation of myelin, the protective substance that covers nerves and promotes the efficient transmission of nerve impulses. Health Conditions Related to Genetic Changes 5q31.3 microdeletion syndrome 5q31.3 microdeletion syndrome is caused by a chromosomal change in which a small piece of chromosome 5 is deleted in each cell. This rare condition is characterized by severely delayed or impaired development of speech and walking, weak muscle tone ( hypotonia), breathing problems, recurrent seizures (epilepsy) or seizure-like episodes, and distinctive facial features. The deletion that causes this condition occurs on the long (q) arm of the chromosome at a position designated q31.3. The size of the deletion can range from several thousand to several million DNA building blocks (base pairs). The deleted region typically contains at least three genes, one of which is PURA. A loss of one copy of the PURA gene is thought to alter normal brain development and impair the function of neurons, leading to developmental delay, hypotonia, and other neurological problems in people with 5q31.3 microdeletion syndrome.
    [Show full text]
  • Deletions of PURA, at 5Q31, and PURB, at 7P13, in Myelodysplastic Syndrome and Progression to Acute Myelogenous Leukemia K Lezon-Geyda1,2, V Najfeld2 and EM Johnson1
    Leukemia (2001) 15, 954–962 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia K Lezon-Geyda1,2, V Najfeld2 and EM Johnson1 1Departments of Pathology, Biochemistry and Molecular Biology, the Derald H Ruttenberg Cancer Center; and 2Tumor Cytogenetics Laboratory, Polly Annenberg Levee Hematology Center, Mount Sinai School of Medicine, New York, NY, USA Deletions or monosomy of chromosomes 5 and 7 are frequently gle gene product, the levels of which are critical, may be con- observed in myelodysplastic syndromes (MDS) and acute myel- ferred by haploinsufficiency.16 Similarly, no tumor suppressor ogenous leukemia (AML). In this study two genes, PURA and PURB, encoding functionally cooperative proteins in the Pur genes have yet been identified at deleted loci on chromosome family, are localized to chromosome bands 5q31.1 and 7p13, 7. The possibility has been noted that tumor suppressor genes respectively. One or both of these loci are shown to be hemiz- are present at more than one site on the long arms of chromo- ygously deleted in 60 MDS or AML patients using fluorescence some 7,17 as deletions of 7q are more frequently seen in MDS in situ hybridization (FISH). High-resolution mapping of PURA patients than deletions in 7p.1 On the other hand, deletions localizes it approximately 1.1 Mb telomeric to the EGR-1 gene. of 7p are seen in a significant number of cases,1,18 and thus Frequency of PURA deletion and segregation with EGR-1 indi- cate that PURA is within the most commonly deleted segment it is conceivable that the high prevalence of monosomy 7 in myeloid disorders characterized by del(5)(q31).
    [Show full text]
  • DNA Damage and Repair, Neurodegeneration and Role Of
    iMedPub Journals ARCHIVES OF MEDICINE 2015 http://wwwimedpub.com Vol. 7 No. 4:5 DNA Damage and Repair, Juan Chai 1*, Yongling Li 2*, Neurodegeneration and the Role Huichen Wang3, of Purα in DNA Repair Jianqi Cui1,2 1 Ningxia Key Laboratory of Cerebrocranial Diseases, the Incubation Base of National Abstract Key Laboratory, Ningxia Medical Univer- A numerous endogenous and exogenous agents can cause DNA damage which sity, Yinchuan, Ningxia Hui Autonomous Region, 750004, China would affect the integrity of genomic materials inside the body. The response to DNA damage is the activation of DNA damage sensing protein ATM and ATR 2 The Institute of Basic Medical Sciences, which trigger the cascade reactivation of repair system to fix the damaged DNA. Ningxia Medical University, Yinchuan, If the damaged DNA was not completely repaired or the ability of DNA repair was Ningxia Hui Autonomous Region, 750004, deficient in the neuron, it would cause a series of fateful consequences such as cell China death, apoptosis or oncogenesis. The deficiency in DNA repair also causes many neurodegenerative diseases. Purα is a ubiquitous nucleic acid-binding protein that 3 Chancellor's Research Initiative (CRI) - was originally purified from the mouse brain based on its ability to bind to a DNA Radiation Institute for Science and Engi- sequence derived from the promoter of the mouse myelin basic protein gene. It is neering (RaISE), College of arts and sci- reported that Purα also played an important role in DNA repair. In this review, we ence, Prairie View A&M University, Minor will discuss the importance of DNA damage and repair in central nervous system, Street 2230, Room 330, Prairie View, TX- the relationship between the DNA damage and neurodegeneration as well as the 77446 function of Purα, especially, the role it played in the DNA repair.
    [Show full text]
  • Mouse Granulin / GRN / Progranulin Protein (His Tag)
    Mouse Granulin / GRN / Progranulin Protein (His Tag) Catalog Number: 50396-M08H General Information SDS-PAGE: Gene Name Synonym: epithelin; Pgrn Protein Construction: A DNA sequence encoding the mouse GRN (NP_032201.2) (Met 1-Leu 589) was fused with a polyhistidine tag at the C-terminus. Source: Mouse Expression Host: HEK293 Cells QC Testing Purity: > 90 % as determined by SDS-PAGE Endotoxin: Protein Description < 1.0 EU per μg of the protein as determined by the LAL method &Granulins are a family of secreted, glycosylated peptides that are cleaved Stability: from a single precursor protein with 7.5 repeats of a highly conserved 12- cysteine granulin/epithelin motif. The precursor protein, progranulin, is also Samples are stable for up to twelve months from date of receipt at -70 ℃ called proepithelin and PC cell-derived growth factor. Cleavage of the signal peptide produces mature granulin which can be further cleaved into Predicted N terminal: Thr 18 a variety of active, 6 kDa peptides. These smaller cleavage products are Molecular Mass: named granulin A, granulin B, granulin C, etc. Epithelins 1 and 2 are synonymous with granulins A and B, respectively. Both the peptides and The secreted recombinant mouse GRN comprises 583 amino acids and intact granulin protein regulate cell growth. However, different members of has a predicted molecular mass of 63 kDa. As a result of glycosylation, the the granulin protein family may act as inhibitors, stimulators, or have dual apparent molecular mass of rmGRN is approximately 70-90 kDa in SDS- actions on cell growth. Granulin family members are important in normal PAGE under reducing conditions.
    [Show full text]